ReviewCurrent treatment options in oncology2006
Ex vivo programmed cell death and the prediction of response to chemotherapy.
Review in Current treatment options in oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer.Journal of translational medicine · 2016Trial
- Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.Cancers · 2026Article
- Article
- A framework for fibrolamellar carcinoma research and clinical trials.Nature reviews. Gastroenterology & hepatology · 2022Review
- Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7.Journal of gastrointestinal oncology · 2021Review
- Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.Theranostics · 2021Review
- The response of phyllodes tumor of the breast to anticancer therapy: AnOncology letters · 2019Article
- Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy.SAGE open medical case reports · 2019Article
- Anti-cancer effect of bee venom on human MDA-MB-231 breast cancer cells using Raman spectroscopy.Biomedical optics express · 2018Article
- Efficacy of oral metformin in a patient with metastatic adrenocortical carcinoma: Examination of mechanisms and therapeutic implications.Rare tumors · 2018Article
- A study of Docetaxel-induced effects in MCF-7 cells by means of Raman microspectroscopy.Analytical and bioanalytical chemistry · 2012Article
- Sensor-based cell and tissue screening for personalized cancer chemotherapy.Medical & biological engineering & computing · 2012Article
- An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Mitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drug.PloS one · 2011Article
- Detection of doxorubicin-induced apoptosis of leukemic T-lymphocytes by laser tweezers Raman spectroscopy.Biomedical optics express · 2010Article
- In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.British journal of cancer · 2008Article
- Methods and goals for the use of in vitro and in vivo chemosensitivity testing.Molecular biotechnology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the earliest introduction of cytotoxic chemotherapy, investigators have pursued laboratory techniques designed to match patients to available drugs. Most of the work, published through the 1980s, reflected the prevailing view of cancer as a disease of dysregulated cell proliferation. Noteworthy, the description of apoptosis and programmed cell death, fundamental to our modern understanding of human tumor biology, did not occur until well after the heyday of in vitro chemosensitivity testing. By incorporating the modern tenets of carcinogenesis associated with perturbations in cell survival we can now re-examine laboratory assays of drug response in the context of drug-induced programmed cell death. Although there is interest in the use of genomic analyses for the prediction of chemotherapy response, the painful recognition that genotype does not equal phenotype will continue to limit broad application of these platforms. Biosystematics instructs that biological pathways rarely follow predicted routes. Efforts to force human biology to behave according to preconceived scientific dictates have proven costly and unsuccessful. Whole-cell experimental models with the capacity to evaluate all the operative mechanisms of cellular response to injury, acting in concert, provide valid tools for the study of human cancer. Educated by cellular behavior, we can expeditiously examine molecular processes of interest. This article briefly reviews the history of whole-cell experimental models of in vitro chemosensitivity testing then focuses on cell-death measures as the most robust predictors of clinical outcome in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.